Peptide Libraray

ACP52C

General Information

DCTPep ID DCTPep01178

Peptide Name ACP52C

Sequence NYPQRPCRGDKGPDC

Sequence Length 15

UniProt ID Not available

PubChem CID Not available

Origin Not available

Type Synthetic peptide

Classification

ACP Tumor active peptide

Activity Information

Hemolytic Activity Not available

Normal (non-cancerous) Cytotoxicity MSC and BEAS-2B: GI50

Target Not available

Affinity Not available

Mechanism Not available

Structure Information

PDB ID Not available

Predicted Structure DCTPep01178

(Please note that there is the predicted structure, predicted by AlphaFold)

Helicity Not available

Linear/Cyclic Linear

Disulfide/Other Bond Not available

N-terminal Modification Free

C-terminal Modification Free

Other Modification None

Chiral L

Physicochemical Information

Formula C69H108N24O23S2

Absent amino acids AEFHILMSTVW

Theoretical pI 8.05

Acidic residues 2

Basic residues 3

Polar residues 6

Molecular weight (Average) 1705.88

Molecular weight (Monoisotopic) 1704.75

Common amino acids P

Net charge 1

Instability index (II) 16.21

Aliphatic index 0.00

Grand average of hydropathicity (GRAVY) -1.920

Half Life
1.4 hours (mammalian reticulocytes, in vitro).
3 min (yeast, in vivo).
>10 hours (Escherichia coli, in vivo).

Extinction coefficients
Ext. coefficient 1615
Abs 0.1% (=1 g/l) 0.947, assuming all pairs of Cys residues form cystines
Ext. coefficient 1490
Abs 0.1% (=1 g/l) 0.873, assuming all Cys residues are reduced

Amino acid distribution

Literature Information

Literature 1

Pubmed ID Not available

Title Not available

Doi Not available

Year Not available

Patent

Patent ID KR20200116394A

Patent Title CP2c Anticancer peptide for targeting CP2c

Other Iinformation Patent Application; Family: 2s / 4ex; Family Jurisdictions: KR; Legal Status: Active; Application No: 20190085790; Filed: Jul 16, 2019; Published: Oct 12, 2020; Earliest Priority: Apr 1, 2019; Granted: Jun 8, 2021

Other Published ID KR102261371B1